Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Core Viewpoint - Emergent BioSolutions Inc. has received a $62.4 million contract modification from the U.S. government to supply Botulism Antitoxin Heptavalent (BAT), reinforcing the importance of its medical countermeasures for public health and emergency preparedness [1][2]. Group 1: Contract and Product Details - The contract modification is part of an existing 10-year agreement with the Administration for Strategic Preparedness and Response (ASPR) [1]. - BAT is used for treating symptomatic botulism after exposure to botulinum neurotoxin serotypes A through G in both adults and pediatric patients [3]. - The effectiveness of BAT is based on animal model studies, with no established safety data for pregnant, nursing, pediatric, or geriatric populations [3]. Group 2: Adverse Reactions and Safety Information - Common adverse reactions in clinical trials include headache, nausea, pruritus, and urticaria, with serious reactions such as hemodynamic instability reported in some cases [4]. - Warnings include potential severe hypersensitivity reactions and interference with blood glucose testing due to maltose content in BAT [6]. Group 3: Company Overview - Emergent BioSolutions has over 25 years of experience in providing protective solutions against health threats like smallpox, botulism, and Ebola [5]. - The company emphasizes its commitment to safeguarding public health and enhancing global emergency preparedness through its supply chain capabilities [2].